Ligand closes acquisition of XOMA Royalty for $39 per share cash
XOMA•Ligand completes XOMA Royalty acquisition
Ligand Pharmaceuticals completed its acquisition of XOMA Royalty, buying all outstanding common shares.
Stockholders received $39 per share in cash under the terms announced April 27, 2026. Holders also received one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation.
XOMA Royalty common stock stopped trading on Nasdaq following the closing.
